Prostate cancer vaccines: Maximizing a suboptimal immune response for improved outcome

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 12, 2007, Pages 972-984

  Slovin, Susan F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Antibody; CTLA 4; Prostate cancer; PSA; T cell; Vaccines

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOVIRUS VECTOR; CANCER ANTIBODY; CANCER VACCINE; CARBON DIOXIDE; CELL SURFACE PROTEIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DOCETAXEL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 4; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MUCIN 1; MUCIN 2; PLACEBO; PLASMID VECTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROVENGE; SIPULEUCEL T; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ANTIGEN DETECTION; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; MALE; NONVIRAL GENE DELIVERY SYSTEM; OVERALL SURVIVAL; POXVIRUS; PROSTATE CANCER; REVIEW; RIGOR; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; DISEASE COURSE; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; SURVIVAL; VACCINATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION;

EID: 40449097910     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Slovin SF, Ragupathi G, Adluri S, et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo hexasaccharide conjugate in man. Proc Natl Acad Sci U S A. 1999;6:5710-5715.
2. Slovin S, Ragupathi G, Israel R, et al. Ganglioside vaccines in relapsed prostate cancer (PC): experience with GM2-KLH conjugate plus the immunologic adjuvant, QS21-A trial comparing QS21 doses. Proc Am Soc Clin Oncol. 1999;18:316a. Abstract 1214.
3. Slovin SF, Ragupathi G, Fernandez C, et al. A polyvalent vaccine for high risk prostate patients: "are more antigens better?" Cancer Immunol Immunother. 2007;56:1921-1930.
4. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 1998;4:295-302.
5. Slovin SF, Livingston P, Zhang S, et al. Targeted therapy in prostate cancer (PC): vaccination with a glycoprotein, MUC-1-KLH-QS21 peptide conjugate. Proc Am Soc Clin Oncol. 1997;16:311a. Abstract 1107.
6. Slovin SF, Ragupathi G, Fernandez C, et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21. Vaccine. 2005;23: 3114-3122.
7. Slovin SF, Ragupathi G, Musselli C, et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with a-N-acerylgalactosamine-o-serine/threonine (Tn) conjugate vaccine. J Clin Oncol. 2003;21:4292-4298.
8. Slovin, SF, Ragupathi G, Fernandez C, et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother. 2005;54:694-702.
9. Ghosh H, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
10. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95: 1735-1740.
11. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281: 1591-1597.
12. Slovin SE How to channel a minimal response for maximal outcome. Curr Opin Urol. 2006;16:179-185.
13. Ragupathi, G Koganty RR, Qiu DX, et al. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn KLH conjugate using a 4-(4-N-maleimidomethyl)cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate. 1998;15:217-221.
14. Helling F, Zhang S, Shang A, et al GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995;55:2783-2788.
15. Simons JW, Mikhak B, Chang J-F, et al. Induction of immunity to prostate cancer antigens: results ofa clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59:5160-5168.
16. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising PSA: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22:537-556.
17. Slovin SF. PSMA vaccines: naked DNA and protein approaches. Clin Prostate Cancer. 2005;4:1-6.
18. Gregor P, Wolchok J, Pedraza A, et al. A xenogeneic PSMA DNA vaccine for patients with noncastrate metastatic and castrate metastatic prostate cancer - a phase I trial of proof of principle. Presented at ASCO Prostate Cancer Symposium. February 22-24, 2007. Abstract 260.
19. Todorova K, Zoubak S, Mincheff M, Kyurkchiev S. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines. Anticancer Res. 2005;25:4727-4732.
20. Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy - A: results from immunizations in animals. Cancer Gene Ther. 2006;13:436-444.
21. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol. 2003;30: 659-666.
22. Dunphy EJ, McNeel DG. Antigen-specific IgG elicited in subjects with prostate cancer treated with Flt 3 ligand. J Immunother. 2005;28:268-275.
23. McNeel DG, Knutson KL, Schiffman K, et al. Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol. 2003;23:62-67.
24. Miller AM, Ozenci V, Kiessling R, Pisa F. Immune monitoring in a phase I trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Imunother. 2005;28:389-395.
25. Pavlenko M, Roos AK, Lundquist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91:688-694.
26. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11:3353-3362.
27. Thomas-Kaskel A-K, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006;119:2428-2434.
28. Gulley JL, Dahut WL. Future directions in tumor immunotherapy: CTLA4 blockade. Nat Clin Pract Oncol. 2007;4:136-137.
29. Leach DR, Krummel MF, Allison JP, et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736.
30. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A. 1999;96:8603-8608.
31. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999;96:15074-15079.
32. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005-1016.
33. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-asxociated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-598.
34. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.
35. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen 4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A. 2002;99:3013-3017.
36. van Elsas A, Hurwitz AA, Allison JF. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-366.
37. van Elsas A, Sutmuller RP, Hurwitz AA. Elucidating the autoimmune and anti-tumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001;194:481-489.
38. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935-1945.
39. Camacho LH, Ribas A, Glaspy JA, et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients with advanced solid malignancies. Proc Am Soc Clin Oncol. 2004;22:164s. Abstract 2505.
40. Jaeger MA, Stroehlein A, Schoberth A, et al. Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study. Proc Am Soc Clin Oncol. 2004;22:154s. Abstract 2504.
41. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539-3543.
42. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther. 2005;12:18-27.
43. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997;57:1537-1546.
44. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006;12:3394-3401.
45. Berns AJ, Clift S, Cohen LK, et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther. 1995;6:347-368.
46. Gerritsen W, Van Den Eertwegh AJ, De Gruijl T, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patient with hormone-refractory prostate cancer (mHRPC). Proc Am Soc Clin Oncol. 2006;24:100s. Abstract 2500.
47. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12:1260-1269.
48. O'Mahoney D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res. 2007;13:958-964.
49. Small EJ, Fratesi O, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18: 3894-3903.
50. Small EJ, Schellhammer PF, Higanc, CS, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
51. Fong L, Kavanagh B, Rini BI, Shaw V, Weinberg V, Small EJ. A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. Proc Am Soc Clin Oncol. 2006;24: Abstract 2508.
52. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1-15.